ReviewEuropean journal of medical research2026
The iron-ferroptosis axis in bone homeostasis: a potential complementary pathway for osteoporosis in endometriosis.
Review in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Endometriosis, a chronic gynecological disorder, is clinically associated with an increased risk of osteoporosis. While this link has been primarily attributed to hypoestrogenism resulting from the disease process or its treatment, this paradigm may not fully capture the underlying pathophysiology. This review proposes a complementary hypothesis centered on the iron-ferroptosis axis. We posit that the chronic pelvic inflammation and significant localized iron overload inherent to endometriosis may establish a systemic pro-oxidative state. This state, we propose, could sensitize bone tissue to ferroptosis-an iron-dependent form of regulated cell death driven by lipid peroxidation-thereby acting as a synergistic factor that exacerbates hormonally driven bone loss. This conceptual framework synthesizes evidence from bone metabolism, reproductive endocrinology, and cell death biology to suggest that systemic iron dysregulation may serve as a mechanistic bridge between localized pelvic pathology and systemic skeletal fragility. By framing the iron-ferroptosis axis as a theoretical potential amplifier of established hormonal mechanisms, this manuscript aims to stimulate new research into the non-hormonal drivers of osteoporosis in women with endometriosis and to identify novel avenues for therapeutic investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.